Topical finasteride vs oral: is it really as effective with less risk?

So is it really as effective? Pretty much, yes. Risk-free? Almost. Not quite.

Recent clinical trials show near-identical hair gain between the topical and the tablet. The amount of finasteride that reaches the bloodstream is more than 100 times lower with the topical. Sexual side effects drop to 2.8%, compared with 4.8% on the oral version. The molecule still slips into general circulation, and blood DHT does fall, less sharply than with the tablet, but not down to zero.

Dr Emrah Cinik has been treating hormonal hair loss for over 20 years, with or without oral finasteride as a complement. So what’s the topical version actually worth in practice?

Topical finasteride: how it works on the scalp

What finasteride does, oral or topical

Both forms block the same enzyme, 5α-reductase, which converts testosterone into DHT. DHT is the hormone that gradually strangles the roots of genetically vulnerable hair on the top of the scalp.

Block the enzyme and you cut DHT production at the source. Follicles stop shrinking. Some of them come back to life.

The difference between the two forms comes down to the route the molecule takes through the body. Once you swallow it, the tablet passes through the liver, circulates everywhere in the bloodstream, reaches the follicles, but also the prostate, the testicles and the brain. Sprayed on the scalp, the molecule heads straight for its target. A useful image: drip-feeding one plant rather than flooding the whole house.

Why a little still ends up in the blood

Topical isn’t airtight. Some of it crosses the skin barrier and reaches the blood, but in proportions nowhere near the oral route.

In the large European trial of 458 men, the blood concentration of finasteride with the 0.25% spray sat between 36 and 48 pg/mL (tiny amounts, in the picogram range). With the 1 mg tablet, the figure was between 5,029 and 7,166 pg/mL. In short, more than 100 times higher with the oral version.

Blood DHT followed the same logic after 24 weeks of treatment:

• Topical: -34.6%
• Oral: -55.6%
• Placebo: barely changed

That’s why topical is better tolerated day to day. It still lowers blood DHT, but roughly half as much as the oral form. Other DHT blockers work on the same principle, with strengths that vary from one molecule to the next.

The real question: does it grow hair as well as the tablet?

Topical vs oral: the figures on effectiveness

The reference study on 458 men

The European trial is the cornerstone of the evidence. 458 men, 24 weeks of treatment, head-to-head comparison between topical 0.25%, oral 1 mg and placebo. The primary endpoint: hair count on a target zone of the scalp.

The gains measured:

• Topical 0.25%: +20.2 hairs
• Oral 1 mg: +21.1 hairs
• Placebo: +6.7 hairs

The gap between topical and oral is statistically not significant, meaning it can’t be told apart from random variation. To the naked eye, the difference is negligible. And 42% of patients on topical were rated as improved by the investigating doctors, against 27.6% in the placebo group.

A wider review of 7 studies and 256 patients points the same way: scalp DHT down by up to 70%, a clear rise in mature hair density across every study analysed, and no loss of effectiveness against the oral form on regrowth.

How long before you see results?

No miracle in two weeks. The first effects measurable under the microscope show up around the 12th week. The gains visible to the naked eye, the ones that change the photo in the mirror, tend to appear at 6 months. Patience is part of the deal.

The good news: results last as long as the treatment continues.

Topical plus minoxidil: the combo that pulls ahead

A trial on 60 men compared three approaches: minoxidil 5% alone, topical finasteride 0.25% alone, and the two together. The verdict: the combination did better than minoxidil on its own.

Mature hair density at 24 weeks:

• Minoxidil + topical finasteride combo: +11.2 hairs/cm²
• Minoxidil alone: +8.45 hairs/cm²

The minoxidil formulation matters too, and some protocols even merge the two molecules into a single bottle. To go further, topical dutasteride also exists in an experimental version, with promising early results. The post-transplant protocol often relies on this kind of pairing.

Sexual side effects: what the studies say

Topical halves the risk

This is the question that tips the balance for most patients. In the large European trial, sexual side effects attributed to treatment broke down like this:

• Topical: 2.8% of patients
• Placebo: 3.3% of patients
• Oral: 4.8% of patients

Topical does barely more than placebo. Oral doubles the rate. Dropouts due to sexual side effects follow the same curve: 0% with topical, against 2.4% with oral.

The local logic holds up: less finasteride in the blood means less impact on the sexual sphere.

And the famous post-finasteride syndrome?

The term sets forums on edge. Post-finasteride syndrome (often shortened to PFS) is when side effects (sexual, mood, “brain fog”) persist after stopping the drug. It’s real, not a rumour cooked up by a handful of angry users.

The documented figures:

• Among users of oral finasteride, 0.8% develop sexual dysfunction during treatment.
• Of those, 33% keep symptoms after stopping.
• The main risk factor: treatment lasting more than 7 months.

Long-term studies on topical finasteride specifically are still missing. In theory, less absorption into the bloodstream should mean lower risk. In practice, caution is the right call, at least until we have more hindsight.

One more thing worth flagging: the nocebo effect carries real weight. It’s the flip side of the placebo effect. When you expect symptoms, you’re more likely to feel them. One study found 43.6% of men told in advance about sexual side effects went on to develop them, against just 15.3% of those not told. Reading anxiety-inducing forums two hours before starting treatment is a near-guaranteed way to summon symptoms. The links between testosterone and hair loss cause concern, and that anxiety alone takes a toll on libido, with no involvement from the molecule itself.

Zero risk doesn’t exist

Best to put it plainly: topical lowers the risk, it doesn’t wipe it out.

Other reported effects: scalp irritation (redness, itching) in less than 1% of patients in the late-phase trial, more frequent in everyday practice. A few headaches and bouts of testicular pain have also been reported. In 2025, the US Food and Drug Administration (FDA) flagged topical products compounded on demand by pharmacies, with no clinical validation, citing sexual and mood disorders as a concern. For that reason, sticking to formulations tested in clinical trials is the safer route.

How to use it in practice

Form and dosage

Several presentations are on the market. The 0.25% alcohol-based spray is the most studied form, and the one used in the major clinical trials. Compounded creams and foams also exist, but with less scientific data behind them.

The validated dosage comes down to a few simple steps:

• 1 to 4 sprays a day (50 to 200 µL depending on the area to treat)
• Apply on a dry or slightly damp scalp
• Massage lightly with the fingertips, then wash your hands
• Let it dry for at least 4 hours before shampooing

How many sprays exactly? It depends on how much surface you need to cover. For an early thinning crown, 1 to 2 are enough. For a 4 cm receding hairline, you’ll want 3 to 4.

Combinations that work

The protocol best supported by the literature: minoxidil 5% in the morning, topical finasteride in the evening. You can top it up with a weekly microneedling session using a dermaroller, which boosts absorption and stimulates the follicles. Oral minoxidil is another option to discuss with a doctor depending on your profile.

Mistakes to avoid

• Applying on a damaged scalp (cut, active eczema): blood absorption rises sharply.
• Mixing with potent essential oils without medical advice: unpredictable interactions.
• Stopping abruptly: possible rebound effect with accelerated shedding over 3 to 6 months.
• Ordering from unregulated foreign sites: variable quality, with a risk of contamination or wrong dosing.

When to see a doctor

Before starting, a hormonal workup and confirmation of the diagnosis are essential. Topical finasteride is no use against hair loss that isn’t hormonal in origin. After 6 months, a response check is in order (standardised photos, scalp assessment). And if sexual disorders, mood disorders or gynaecomastia (abnormal breast tissue development in men) appear, see a doctor before stopping on your own.

Other options exist depending on the case, including topical clascoterone, natural DHT blockers or full baldness treatments. For early-onset baldness, the approach has to be more proactive.

What to do when finasteride isn’t enough anymore

Topical finasteride slows hair loss and helps regrow hair that’s still there but miniaturised. What it doesn’t do: bring dead follicles back to life. On a zone that’s been bare for years, there’s nothing left for medication to save. And the benefit only holds at the cost of lifelong treatment: stop, and the regrown hair falls out within a few months.

When medication is no longer enough, the FUE transplant takes over. Dr Cinik takes follicles from the donor area (the back of the neck, where hair is genetically insensitive to DHT) and replants them where they’re missing. Sapphire FUE uses sapphire blades for faster healing and higher density. DHI pushes precision further, and is ideal for hairlines.

Hair PRP, included in every transplant package, improves graft take and stimulates native hair. Hair exosomes and mesotherapy round out the toolkit for borderline cases. The before/after results speak for themselves, and post-transplant progress builds over 12 to 18 months.

Over 20 years of experience, more than 50,000 patients operated on, protocols in line with ISHRS standards. Looking for a hair transplant in Turkey? A free consultation is the right place to start. Topical finasteride can be enough for a 28-year-old at the start of hair loss. For more advanced baldness, the strategy usually combines medication and surgery. Send your photos for a first remote opinion.

Scientific references

Piraccini, B. M., Blume-Peytavi, U., Scarci, F., Jansat, J. M., Falqués, M., Otero, R., Tamarit, M. L., Galván, J., Tebbs, V., Massana, E., & Topical Finasteride Study Group. (2022). Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: A phase III, randomized, controlled clinical trial. Journal of the European Academy of Dermatology and Venereology, 36(2), 286-294. https://pmc.ncbi.nlm.nih.gov/articles/PMC9297965/

Lee, S. W., Juhasz, M., Mobasher, P., Ekelem, C., & Mesinkovska, N. A. (2018). A systematic review of topical finasteride in the treatment of androgenetic alopecia in men and women. Journal of Drugs in Dermatology, 17(4), 457-463. https://pmc.ncbi.nlm.nih.gov/articles/PMC6609098/

Keerti, A., Koneru, S., Keerti, A., Yeola (Pate), M., & Sahu, P. (2023). Topical finasteride: A comprehensive review of androgenetic alopecia management for men and women. Cureus, 15(9), e44949. https://pmc.ncbi.nlm.nih.gov/articles/PMC10561660/

Bharadwaj, D., Mishra, S., & Yadav, A. K. (2023). Comparative efficacy of topical finasteride (0.25%) in combination with minoxidil (5%) against 5% minoxidil or 0.25% finasteride alone in male androgenetic alopecia: A pilot, randomized open-label study. International Journal of Trichology, 15(4), 154-160. https://pmc.ncbi.nlm.nih.gov/articles/PMC10495069/

Diviccaro, S., Melcangi, R. C., & Giatti, S. (2020). Post-finasteride syndrome: An emerging clinical problem. Neurobiology of Stress, 12, 100209. https://pmc.ncbi.nlm.nih.gov/articles/PMC7231981/

Panuganti, B., Shenoy, P., Vijayan, G., Sreejayan, M. P., Sundararajan, V. K., Thakkar, K., Hota, D., & Padmaja, U. (2025). A randomized, double-blind, placebo and active controlled study of topical dutasteride solution in male androgenetic alopecia. Dermatology and Therapy, 15(3), 501-518. https://pmc.ncbi.nlm.nih.gov/articles/PMC12405733/

Hirshburg, J. M., Kelsey, P. A., Therrien, C. A., Gavino, A. C., & Reichenberg, J. S. (2016). Adverse effects and safety of 5-alpha reductase inhibitors (finasteride, dutasteride): A systematic review. Journal of Clinical and Aesthetic Dermatology, 9(7), 56-62. https://pmc.ncbi.nlm.nih.gov/articles/PMC4964109/